Prasugrel Shows Best Efficacy-Safety Balance After PCI Compared to Ticagrelor and Clopidogrel: JAMA
USA: A systematic review and meta-analysis of 15 randomized clinical trials has revealed that among patients undergoing percutaneous coronary intervention (PCI), prasugrel achieved the most favorable balance between reducing ischemic events and maintaining safety when compared with ticagrelor and clopidogrel. The findings suggest prasugrel may offer superior overall clinical outcomes in appropriately selected PCI patients.
The study, published in JAMA Cardiology, was conducted by M. Haisum Maqsood and colleagues from The Methodist Hospital. The researchers aimed to clarify the relative benefits and risks of the three commonly used oral P2Y12 receptor inhibitors—prasugrel, ticagrelor, and clopidogrel—in patients undergoing PCI, a widely performed procedure to open narrowed or blocked coronary arteries in individuals with coronary artery disease.
The analysis included data from 48,904 patients drawn from randomized clinical trials identified through systematic searches of PubMed and Embase up to November 2025. The included studies followed PRISMA guidelines and used random-effects models to ensure robust pooled estimates. The mean age of participants was 63.2 years, and approximately 27% were women, reflecting a typical real-world PCI population at elevated cardiovascular risk.
The primary efficacy endpoint was major adverse cardiovascular events (MACE), while the primary safety endpoint was major bleeding.
The following were the key findings:
- Prasugrel significantly reduced the risk of major adverse cardiovascular events compared with clopidogrel, primarily due to lower rates of myocardial infarction and stent thrombosis.
- These results indicate stronger anti-ischemic efficacy of prasugrel in patients after percutaneous coronary intervention.
- Prasugrel also showed a modest but statistically significant reduction in MACE compared with ticagrelor, driven by fewer myocardial infarctions and stent-related complications.
- Ticagrelor did not significantly reduce overall MACE when compared with clopidogrel, although it did lower the risk of stent thrombosis.
- Ticagrelor was associated with a higher risk of major bleeding compared with clopidogrel, including an increased incidence of intracranial hemorrhage.
- Prasugrel demonstrated a more balanced safety profile while maintaining superior protection against ischemic events.
- Across all assessed outcomes, prasugrel consistently ranked highest for efficacy endpoints, including MACE, myocardial infarction, and stent thrombosis.
- Overall ranking of efficacy was prasugrel first, followed by ticagrelor and then clopidogrel, indicating a more favorable overall clinical profile for prasugrel in appropriately selected PCI patients.
The authors concluded that prasugrel appears to provide the best overall balance between reducing ischemic complications and maintaining acceptable bleeding risk among the three P2Y12 inhibitors. However, they emphasized that treatment decisions should still be individualized, taking into account patient-specific bleeding risk, comorbidities, and clinical presentation.
Overall, the findings provide important comparative evidence that may help guide clinicians in optimizing antiplatelet therapy after PCI, with the potential to improve long-term cardiovascular outcomes in patients with coronary artery disease.
Reference:
Maqsood MH, Feit F, Kaul U, et al. Efficacy and Safety of Prasugrel, Ticagrelor, or Clopidogrel After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. JAMA Cardiol. Published online May 27, 2026. doi:10.1001/jamacardio.2026.1128
Next Story